Neurocrine Biosciences, Inc. Stock Sao Paulo
Equities
N1BI34
BRN1BIBDR009
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36 BRL | -1.96% | -0.22% | +11.46% |
Sales 2024 * | 2.22B 12.07B | Sales 2025 * | 2.55B 13.88B | Capitalization | 13.17B 71.65B |
---|---|---|---|---|---|
Net income 2024 * | 431M 2.34B | Net income 2025 * | 675M 3.67B | EV / Sales 2024 * | 5.03 x |
Net cash position 2024 * | 2B 10.88B | Net cash position 2025 * | 2.81B 15.29B | EV / Sales 2025 * | 4.06 x |
P/E ratio 2024 * |
32.3
x | P/E ratio 2025 * |
20.6
x | Employees | 1,448 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | -1.96% | ||
1 week | -0.22% | ||
Current month | +1.81% | ||
1 month | -0.77% | ||
3 months | +1.44% | ||
6 months | +22.16% | ||
Current year | +11.46% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-18 | 36 | -1.96% | 1 |
24-06-17 | 36.72 | +0.88% | 15 |
24-06-14 | 36.4 | +0.89% | 3,000 |
Delayed Quote Sao Paulo, June 18, 2024 at 03:45 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
+21.87% | 11.11B | |
+111.62% | 10.57B |
- Stock Market
- Equities
- NBIX Stock
- N1BI34 Stock